, Columnist
Vaccine Muddle Is Reputational Risk for AstraZeneca
The British drugmaker will likely conduct an additional global trial for the Oxford inoculation. It’s got to be careful how it presents the results.
Additional trials likely.
Photographer: Vincenzo Pinto/AFP via Getty Images
This article is for subscribers only.
AstraZeneca Plc’s work to turn Oxford University research into a widely distributed vaccine against Covid-19 may be financially cost-free for the British drugmaker thanks to funding from outside sources. But it clearly has taken on some additional reputational risk.
The presentation of late-stage trial data this week has become a problem. AstraZeneca and Oxford presented efficacy results that differed for two separate dosages. It wasn’t clear what made one course better than the other.